CRESCENT BIOPHARMA, INC. (CBIO) Market Cap & Valuation Ratios
CRESCENT BIOPHARMA, INC. (CBIO) has a market cap of $476.2M and a price-to-sales ratio of 40.1, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CBIOCRESCENT BIOPHARMA, INC.Follow CBIO — free
—
Price chart with a free account
- Market cap
- 476.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
drug manufacturers - general · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| CBIO | 0.5 | — | 25.6 | — | — | — | — | — |
| NVCT | 0.7 | — | — | — | — | — | — | — |
| GYRE | 0.7 | — | 5.0 | — | -0.9% | +17% | -14% | -28% |
| AKTX | 0.6 | — | — | — | -1.6% | — | — | -175% |
| PBYI | 0.6 | 21.2 | 2.1 | 11.6 | 7.2% | -3% | 13% | 27% |
| STTK | 0.6 | — | 487.7 | — | -7.5% | -67% | — | -72% |
| DMAC | 0.5 | — | — | — | -6.7% | — | — | -139% |
| OVID | 0.4 | — | 192.4 | — | -13.0% | -76% | — | -52% |
| ASMB | 0.4 | — | 1.1 | — | -9.5% | +125% | -12% | -3% |
| RZLT | 0.4 | — | — | — | — | — | — | -105% |
| NBP | 0.4 | — | — | — | -5.6% | — | — | -587% |
| Median of these 10 | 21.2 | 5.0 | 11.6 | -6.2% | -3% | -12% | -72% |
; EV/Sales 25.6 vs. 5.0.
Growth vs. price
each dot a company · hover or tap for valuesCRESCENT BIOPHARMA, INC. — questions
- What is CRESCENT BIOPHARMA, INC.'s market cap?
- $476.2M.
- What is CRESCENT BIOPHARMA, INC.'s price-to-sales ratio?
- 40.1.
Every figure on this page comes from CRESCENT BIOPHARMA, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.